2025 NMPA Approvals: China Clears Record Number of New Drugs
With the tremendous development of China’s innovative drug industry as backdrop, 2025 saw the number of new drugs approved by the National Medical Products Administration (NMPA)—the …
Appendix: New drugs approved by the NMPA in 2025
Dec 30, 2025 · Comprehensive list of new drugs approved by China’s NMPA in 2025, including chemical and biologic therapies, targets, disease indications, and approval dates.
New Drug Approvals in China in 2021 - DIA Global Forum
The number of new drug approvals in China set a new record high in 2021. A total of 61 new drugs were approved by the National Medical Products Administration (NMPA), up from 46 in 2020. “New drug” …
China Focusing Innovation Through ICH Global Regulatory Vision
Jul 1, 2022 · By translating and implementing ICH guidelines in the four years between June 2017 and DIA China 2021, NMPA has helped lead overall positive change to China’s drug regulatory system …
NMPA Plans to Start PIC/S Accession Procedure in 2023
PIC/S and NMPA are reported to be in close contact for further steps. For the formal accession, it is most important that the NMPA’s inspection criteria are equivalent with PIC/S’s. The PIC/S GMP …
Global Pharmaceutical Regulation Evolving and Modernizing to Protect ...
A series of important policies enacted in the past five years by the NMPA is a particularly prominent model for reforming pharmaceutical regulations. On May 10, 2021, the NMPA outlined their opinions …
China GVP: Lifecycle Pharmacovigilance and Patient Safety
Dec 1, 2021 · In May 2021, the National Medical Products Administration (NMPA) in China issued an announcement about Good Pharmacovigilance Practice (NMPA/Decree No.65/2021), hereafter …
Evolving Policies and Use of RWE in Regulatory Decisions in China
The NMPA RWE Research Project is an important part of China’s strategy to promote innovation in the pharmaceutical industry, reduce the time and cost of drug research and development, and improve …
China’s NMPA Takes Action to Participate in PIC/S
Since initiating the process of pre-admission to the Pharmaceutical Inspection Co-operation Scheme (PIC/S) in September 2021, the National Medical Products Administration (NMPA) has been actively …
China’s Evolving Role: From Harmonization to Source of Innovative ...
This integration has not only boosted international confidence in Chinese drug quality but also strengthened China’s voice in global rule-making through participation in 45 ICH working groups, and …